|Primary analysis complete
|Study Start Date:
|Study Made Public:
A Phase 1 placebo-controlled clinical trial to evaluate the safety and immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis subtype C gp140 with MF59 adjuvant in various vaccination schedules in HIV-uninfected healthy vaccinia-naive adult participants in South Africa
HVTN 086 (SAAVI 103) is a Phase I clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using combinations of SAAVI DNA-C2, SAAVI MVA-C, and subtype C gp140 with MF59.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.